GEN501 Clinical Trial / Bone Marrow

The objective of this study was to identify novel changes in immune cell phenotypes that correlate with the efficacy and depth of response observed during treatment with daratumumab in patients with relapsed refractory multiple myeloma.
Conclusion:
CyTOF® analysis of patient samples from studies of daratumumab therapy highlight the immune-modulatory mechanism of action of daratumumab. T-cell changes toward a cytolytic, granzyme B+ phenotype observed in WB and BM and increased expression of the activation markers on NK cells, such as CD69, support an adaptive response in patients that may contribute to the depth of response observed in patients treated with daratumumab Each experiment includes a full panel stained WB healthy volunteer control sample, a panel minus CD38 metal (FMO) stained control WB sample and a full panel stained PBMC sample. Data acquired on CyTOF® were collected in an FCS file format and normalized using CyTOF® Software 6.5.358 for Stand-Alone Processing Workstations (Fluidigm). To ensure that every cell population was represented, the analysis included only samples in which at least 10,000 events in the lymphocyte/monocyte population had been recorded.